Rizvi et al. reported that four NSCLC patients with POLE mutation achieved a progression free survival of 8–14 months after treatment with pembrolizumab, suggesting that the efficacy of anti-PD-1 therapy is higher in NSCLC with POLE mutation [69]. Here, POLE is linked to non-small cell lung carcinoma.